Single-dose Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial.

Background: Checkpoint inhibitors have been shown to have limited activity in patients with metastatic castration-resistant prostate cancer. We aimed to determine whether a single dose of lutetium-177 [Lu]-prostate-specific membrane antigen (PSMA)-617 (Lu-PSMA-617) followed by maintenance pembrolizumab was safe and could induce durable clinical benefit.

Methods: We did an open-label, dose-expansion, phase 1 study at the University of California, San Francisco (San Fransisco, CA, USA).